Please provide your email address to receive an email when new articles are posted on . A phase 3 randomized controlled trial demonstrated the safety and efficacy of Uceris tablets for induction of ...

Findings reinforce the benefits of Asacol for ulcerative colitis patients AVENTURA, Fla., Dec. 5 -- Data from two Phase III clinical trials support that Asacol, an oral, non-steroidal medication that ...

LIALDA tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Safety and effectiveness of LIALDA beyond eight weeks have not been ...

Basingstoke, UK and Philadelphia, US – January 16, 2007 -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that the U.S. Food and Drug Administration (FDA) has approved LIALDA TM ...

To induce remission in active, mild-to-moderate ulcerative colitis. Mesalamine is an anti-inflammatory agent that is commonly used as a treatment for the induction of remission in patients with ...

Please provide your email address to receive an email when new articles are posted on . Sun Pharmaceutical Industries received FDA approval of its abbreviated new drug application for mesalamine ...

(B) The report delivers a comprehensive analysis of global, regional, and country-level Mesalamine market revenues, extending projections until 2030. This dataset empowers companies to gauge their ...

At Week 8, combined clinical and endoscopic remission was obtained in 13.0% of budesonide MMX patients vs. 7.5% of placebo patients. Salix announced the publication of study data for budesonide ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced the launch of mesalamine 800 mg ...

Attorneys general from Colorado and 19 other states on Friday called for a court to consider rejecting a U.S. Department of Justice's settlement allowing Hewlett-Packard Enterprise to acquire Juniper ...